Viracta Therapeutics (NASDAQ:VIRX) Stock Price Up 2.2% – Here’s What Happened

Viracta Therapeutics, Inc. (NASDAQ:VIRX)’s stock price traded up 2.2% during trading on Friday . The company traded as high as $0.24 and last traded at $0.23. 69,368 shares were traded during mid-day trading, a decline of 75% from the average session volume of 280,198 shares. The stock had previously closed at $0.23.

Analysts Set New Price Targets

VIRX has been the subject of several research analyst reports. Royal Bank of Canada decreased their price target on shares of Viracta Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a research note on Thursday, August 15th. Leerink Partners downgraded Viracta Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $5.00 to $3.00 in a research note on Friday, August 16th.

Viracta Therapeutics Stock Performance

The firm has a market cap of $9.15 million, a P/E ratio of -0.19 and a beta of 0.70. The stock’s 50 day simple moving average is $0.30 and its 200 day simple moving average is $0.60.

Viracta Therapeutics (NASDAQ:VIRX) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.10. As a group, analysts forecast that Viracta Therapeutics, Inc. will post -0.69 EPS for the current fiscal year.

Viracta Therapeutics Company Profile

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.